Clinical trials: Estrogen
Pulmonary Arterial Hypertension
TranspulmonarY Estrogen Gradient and Estrogen Receptors (TYEGER) in PAH
Pulmonary arterial hypertension (PAH) is a disease characterized by elevated pressures in the blood vessels of the lungs that is not caused by another disease processes.
- Trial name
- TYEGER (NCT04280523)
- Testing
- ESR-specific PET scan
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Postmenopause
Use of the Synthetic Hormone CDB-2914 in Treating Symptoms of Menopause
This study will examine the safety and effectiveness of a synthetic hormone, CDB-2914, for treating symptoms of menopause. It will compare the effects of estrogen and CDB-2914 with those of estrogen and progesterone in…
- Trial name
- NCT00009659
- Testing
- CDB 2914
- Where
- United States
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor
Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer
RATIONALE: Estrogen can cause the growth of tumor cells. Hormone therapy using therapeutic estradiol may fight breast cancer by lowering the amount of estrogen the body makes.
- Conditions
- Estrogen Receptor-positive Breast Cancer, Progesterone Receptor Positive Tumor, Recurrent Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- NCT01385280
- Testing
- therapeutic estradiol, exemestane, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Arizona
ER+ Breast Cancer
Study of the Effect of the Addition of SNDX-275 (Entinostat) to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing
The addition of entinostat to an AI will result in a maximal abrogation of estrogen receptor-α mediated activity and inhibit mechanisms of resistance to the aromatase inhibitor.
- Trial name
- NCT00828854
- Testing
- Entinostat, Aromatase Inhibitor (AI) Therapy
- Where
- 6 sites in Ireland, United Kingdom
- Volunteers
- 27 people
- Sponsor
- Syndax Pharmaceuticals
Breast Neoplasms
The Efficacy of Fulvestrant in ESR1(Estrogen Receptor 1) Mutated Metastatic Breast Cancer
This is an open-label, single arm, phase II trial to evaluate the efficacy and safety of 500mg Fulvestrant (Faslodex®) in ESR1 mutated postmenopausal women with hormone receptor positive, HER2 negative locally advanced or…
- Trial name
- NCT03202862
- Testing
- Fulvestrant
- Volunteers
- 50 people
- Sponsor
- Fudan University
Atherosclerosis, Chlamydia Infections
Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections
Hardening of the arteries (atherosclerosis) and heart disease are much more common in men than in women. However, as women grow older, especially after menopause the incidence of atherosclerosis and heart disease increases.
- Conditions
- Atherosclerosis, Chlamydia Infections, Cytomegalovirus Infections, Pneumonia, Bacterial
- Trial name
- NCT00001890
- Testing
- Estrogen therapy
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Breast Neoplasms
A Study to Evaluate the Safety of Adjuvant Treatment With Exemestane Following Previous Treatment With Tamoxifen in Postmenopausal Women With Estrogen Sensitive Primary Breast Cancer
The purpose of this study was to give access to postmenopausal women with estrogen sensitive primary breast cancer to exemestane for the adjuvant treatment of breast cancer after the use of tamoxifen and to collect all serious…
- Trial name
- NCT00649090
- Testing
- exemestane
- Where
- 61 sites in Belgium
- Volunteers
- 1,549 people
- Sponsor
- Pfizer
Breast Cancer
Sunitinib Malate and Exemestane in Treating Postmenopausal Women With Breast Cancer
RATIONALE: Sunitinib malate and exemestane may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00931450
- Testing
- exemestane, sunitinib malate
- Where
- Spain
- Volunteers
- 70 people
- Sponsor
- Institut Català d'Oncologia
Healthy
Comparison of Blood Levels of Two Formulations of the Selective Hormone Receptor Modulator CDB-2914
This study will compare blood levels of the drug CDB-2914 in healthy women receiving the compound in crystalline powder form with the blood levels of women receiving an identical dose of the drug in micronized form.
- Trial name
- NCT00041899
- Testing
- CDB-2914, COB-2914
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
This phase II trial studies the side effects and how well letrozole and imatinib mesylate work in treating postmenopausal participants with estrogen or progesterone positive breast cancer that has spread to other places in the…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Positive, KIT Positive, PDGFR Positive
- Trial name
- NCT00338728
- Testing
- Imatinib Mesylate, Letrozole
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- M.D. Anderson Cancer Center
Infertility
Timing of Estrogen Support During the Luteal Phase of in Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycle
To test the hypothesis that adding estradiol (E2) to progesterone supplementation later in the luteal phase of in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) cycles, rather than earlier in the luteal phase…
- Trial name
- NCT01367912
- Testing
- estradiol tablet
- Where
- Turkey (Türkiye)
- Volunteers
- 301 people
- Sponsor
- Zekai Tahir Burak Women's Health Research and Education Hospital
Depressive Disorder, Mood Disorder
Progestin (Progesterone-Like Hormones) Induced Dysphoria (Depressed Mood, Irritability, Anxiety)
Often women are prescribed hormone replacement therapy (HRT) during the perimenopause or menopause. Hormone replacement therapy includes both estrogen and progesterone.
- Conditions
- Depressive Disorder, Mood Disorder, Psychomotor Agitation
- Trial name
- NCT00001770
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Cardiovascular Diseases, Heart Failure, Congestive
Estrogen, Cytokines and Heart Failure in Women
To determine the effects of estrogen therapy on postmenopausal women with congestive heart failure.
- Conditions
- Cardiovascular Diseases, Heart Failure, Congestive, Heart Diseases, Menopause
- Trial name
- NCT00041431
- Testing
- Hormone Replacement Therapy
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Bipolar Disorder, Circadian Rhythm
Effects of Sex Hormones on Circadian Rhythm in Men and Women
For many years researchers have been trying to better understand the regulation of sleep and activity by studying circadian (daily) rhythms of human beings.
- Conditions
- Bipolar Disorder, Circadian Rhythm, Depressive Disorder
- Trial name
- NCT00001285
- Where
- United States
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- National Institute of Mental Health (NIMH)
Sleep Disorders
Growth Hormone Releasing Hormone (GHRH) Treatment for Age-Related Sleep Disturbances
The purpose of this study is to examine the effects of giving growth hormone releasing hormone (GHRH) to treat sleep disorders in older men and in older women who are on estrogen replacement therapy (ERT).
- Trial name
- NCT00000380
- Testing
- GHRH
- Sponsor
- University of Washington
Breast Neoplasms
Assessment of Safety and Efficacy of Estetrol in Postmenopausal Women With Advanced Estrogen Receptor Positive (ER+) Breast Cancer
This is a multi-center, open-label, phase I/IIa trial, dose-escalation study with a 3 + 3 cohort design to determine the recommended dose of estetrol for the treatment of patients with advanced breast cancer.
- Trial name
- NCT02718144
- Testing
- Estetrol
- Where
- 2 sites in Germany
- Volunteers
- 12 people
- Sponsor
- Pantarhei Oncology B.V.
Hormone
Effects of Infant Diets on Estrogen Activity and Development
This study, conducted at the Children's Hospital of Boston and the Brigham and Women's Hospital in Boston, will examine the natural history of infant development in the first year of life and how different types of infant feeding…
- Trial name
- NCT00340652
- Where
- 2 sites in United States
- Volunteers
- 157 people
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Amenorrhea
Retrospective Observational Evaluation of the Bone Mineral Density Outcome in Young Women With Amenorrhea
The study aims to evaluate the outcomes of different estrogen therapy regimens in patients with amenorrhea who face prolonged periods of hypoestrogenism.
- Trial name
- NCT07015476
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Vaginitis Atropic, Pelvic Organ Prolapse
Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients
To evaluate the difference of three vaginal estrogens creams comparative with placebo on improvement of hormonal cytology, local and systemic climacteric complaints, as well as its endometrial security.
- Conditions
- Vaginitis Atropic, Pelvic Organ Prolapse, Endometrial Hyperplasia
- Trial name
- NCT03032848
- Testing
- Conjugated Estrogen, Promestriene, Estriol
- Volunteers
- 69 people
- Sponsor
- Universidade Federal do Paraná
Breast Cancer
Collection of Efficacy and Safety Data of Chinese Patients Who Have Received Faslodex 250mg Treatment
This study is a post-authorisation study, committed to Center for Drug Evaluation (CDE) and China Food and Drug Administration (CFDA), in order to provide more effectiveness and safety data about Faslodex in real world clinical…
- Trial name
- NCT01425294
- Where
- 23 sites in China
- Volunteers
- 231 people
- Sponsor
- AstraZeneca